Navigation Links
Inspiration Biopharmaceuticals Announces New Global Commercialization Agreements with Ipsen

CAMBRIDGE, Mass., Aug. 21, 2012 /PRNewswire/ -- Inspiration Biopharmaceuticals Inc. (Inspiration) today announced new license, development and commercialization agreements with its strategic partner, Ipsen (Euronext: IPN, ADR: IPSEY). The agreements restructure the existing partnership with Ipsen and provide Inspiration with additional funding to support development of its two investigational drugs in late-stage development for hemophilia, IB1001 and OBI-1. Under the terms of these agreements, Inspiration grants Ipsen commercialization rights for IB1001 (recombinant human factor IX) and OBI-1 (recombinant porcine factor VIII) in certain geographies. Inspiration will receive a $30 million up-front payment, with additional payments and investments linked to future development and commercial milestones, for a total potential value of $200 million. This includes a commitment from Ipsen to fund a significant percentage of Inspiration's next round of external financing.

Ipsen gains rights to commercialize IB1001 and OBI-1 in Europe, Russia, China, Australia and certain other countries, and will be responsible for future regulatory filings in those regions. Inspiration retains commercialization rights in the Americas, Japan, India, the Middle East, South Africa, Taiwan and certain other countries, as well as global development rights for all products in Inspiration's product portfolio. Each company is obligated to pay the other royalties generated by sales of OBI-1 in their respective geographies and Ipsen will pay Inspiration royalties on sales of IB1001.

Under the terms of the new agreements, after the completion of a $30 million qualified external financing Ipsen will invest an additional $20 million in Inspiration and will no longer have a call option to acquire Inspiration, giving Inspiration the ability to develop as an independent entity. Ipsen gains the right to appoint two additional Directors to Inspiration's Board.

"During the last two years, Ipsen's commitment to hemophilia and their recognition of the value of Inspiration's unique product portfolio have been the basis for a successful collaboration," said John P. Butler, Chief Executive Officer of Inspiration. "This new arrangement confirms Ipsen's ongoing commitment to Inspiration, while also enabling Inspiration to become an independent, fully integrated, commercial biopharmaceutical company serving people living with hemophilia." 

Inspiration and Ipsen's strategic partnership began in January 2010, and in August of 2011 was expanded in preparation for the commercial launch of Inspiration's first hemophilia products in Europe. The 2011 agreement established a European commercial partnership, which was designed to leverage the combined strengths of Ipsen's well-established European commercial infrastructure and medical network with Inspiration's expertise in the field of hemophilia. The new agreements announced today will replace the previous European commercial partnership agreement.

About Inspiration BiopharmaceuticalsAs the only biopharmaceutical company dedicated solely to hemophilia, Inspiration is committed to improving the care of people with this condition by broadening treatment choices, expanding global access to care, and advancing innovative therapies. Founded by two families whose sons have hemophilia, Inspiration is inspired to make a difference in the lives of people impacted by hemophilia around the world. Inspiration's lead product candidates are IB1001, an investigational intravenous recombinant factor IX being developed for the treatment of hemophilia B and OBI-1, an investigational recombinant porcine factor VIII being developed for the treatment of serious bleeds in patients with congenital hemophilia A with inhibitors or acquired hemophilia A.

For more information about Inspiration Biopharmaceuticals, please visit Further InformationMedia 

 InvestorsDan Quinn Gordon H. BusenbarkFeinstein Kean Healthcare 

 Senior Vice President, Chief Financial OfficerTel: +1-617-577-8110

 Tel: +1-617-588-1802Email:

SOURCE Inspiration Biopharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Inspiration Biopharmaceuticals Expands Industry Expertise with Five New Executive Hires
2. Inspiration Biopharmaceuticals Announces Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for People with Hemophilia B
3. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
4. Mangrove Partners Sends Letter to Stockholders of Nabi Biopharmaceuticals
5. Global Biopharmaceuticals Market 2011-2015
6. Keryx Biopharmaceuticals to Present at The 7th Annual JMP Securities Healthcare Conference
7. Keryx Biopharmaceuticals Announces Live Webcast of Upcoming Analyst Day
8. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
9. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
10. UBM Announces Partnership Agreement With Trade Organisation - SIPPO
11. Response Genetics, Inc. Announces Second Quarter Financial Results
Post Your Comments:
(Date:11/24/2015)... KUALA LUMPUR, Malaysia , Nov. 24, 2015 ... the global contract research organisation (CRO) market. The ... to result in lower margins but higher volume ... With increased capacity and scale, however, margins in ... Contract Research Organisation (CRO) Market ( ...
(Date:11/24/2015)... Nov. 24, 2015 /CNW/ - iCo Therapeutics ("iCo" or ... financial results for the quarter ended September 30, ... Canadian dollars and presented under International Financial Reporting ... ," said Andrew Rae , President ... iCo-008 are not only value enriching for this ...
(Date:11/24/2015)... 24, 2015  Clintrax Global, Inc., a worldwide provider of clinical ... today announced that the company has set a new quarterly earnings ... on quarter growth posted for Q3 of 2014 to Q3 of ... Mexico , with the establishment of an ... --> United Kingdom and Mexico ...
(Date:11/24/2015)... SHPG ) announced today that Jeff Poulton , ... Annual Healthcare Conference in New York City ... (1:30 p.m. GMT). --> SHPG ) announced today that ... Piper Jaffray 27 th Annual Healthcare Conference in ... at 8:30 a.m. EST (1:30 p.m. GMT). --> Shire ...
Breaking Biology Technology:
(Date:10/29/2015)... 2015  Connected health pioneer, Joseph C. Kvedar ... technology-enabled health and wellness, and the business opportunities that ... The Internet of Healthy Things . Long before ... existed, Dr. Kvedar, vice president, Connected Health, Partners HealthCare, ... moving care from the hospital or doctor,s office into ...
(Date:10/29/2015)... 29, 2015 Today, LifeBEAM , ... with 2XU, a global leader in technical performance ... hat with advanced bio-sensing technology. The hat will ... monitor key biometrics to improve overall training performance. ... two companies will bring together the most advanced technology, ...
(Date:10/27/2015)... 2015 Munich, Germany ... technology (ASGM) automatically maps data from mobile eye tracking ... , so that they can be quantitatively analyzed with ... Munich, Germany , October 28-29, 2015. SMI,s Automated ... mobile eye tracking videos created with SMI,s Eye ...
Breaking Biology News(10 mins):